Alector, Inc. (ALEC)
| Market Cap | 671.41M |
| Revenue (ttm) | 96.31M |
| Net Income (ttm) | -141.39M |
| Shares Out | 84.14M |
| EPS (ttm) | -1.70 |
| PE Ratio | n/a |
| Forward PE | 526.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 372,954 |
| Open | 8.01 |
| Previous Close | 8.00 |
| Day's Range | 7.81 - 8.06 |
| 52-Week Range | 3.66 - 9.86 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 14.67 (+83.84%) |
| Earnings Date | Feb 27, 2024 |
About ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The compa... [Read more]
Financial Performance
In 2022, Alector's revenue was $133.62 million, a decrease of -35.48% compared to the previous year's $207.09 million. Losses were -$133.31 million, 267.0% more than in 2021.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ALEC stock is "Buy." The 12-month stock price forecast is $14.67, which is an increase of 83.84% from the latest price.
News
These biotechs targeting multiple neurodegenerative diseases
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive...
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively Leading scientific and clinical experts to p...
Alector to Participate in the Stifel Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partici...
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pion...
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will pa...
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partici...
Alector Reports First Quarter 2023 Financial Results and Provides Business Update
On track to engage with regulatory authorities on the pivotal Phase 3 INFRONT-3 clinical trial of latozinemab in mid-2023; targeting data readout in early 2025
Alector to Participate in the BofA Securities 2023 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will particip...
Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer's disease in Q3 2023, with data readout expected by Q4 2024
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announ...
Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer's disease
Alector Announces Promotion of Clare Hunt to Chief People Officer
Promotion demonstrates Alector's commitment to building a world-class culture that questions convention, embraces feedback and promotes development for all employees
Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD)
AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD
Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partici...
Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation co...
Alector to Participate at the BofA Securities 2022 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will particip...
Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gar...
Moore Kuehn, PLLC Encourages Investors of Alector, Inc. to Contact Law Firm
New York, New York--(Newsfile Corp. - March 24, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDA...
Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial
Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients
Alector to Participate at the Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therap...
Alector Reports Fourth Quarter and Full Year 2021 Financial Results
CTAD and SITC presentations in fourth quarter highlight progress across immuno-neurology and immuno-oncology portfolio
Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therape...
Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sara...